مقایسهٔ روش‌ها

	شاخص فعالیت بیماری در اسپوندیلیت آنکیلوزان حمام (BASDAI)	امتیاز فعالیت بیماری ۲۸ مفصلی (DAS28)	ارزیابی معمول داده‌های شاخص بیمار ۳ (RAPID3)	شاخص فعالیت بیماری لوپوس اریتماتوی سیستمیک ۲۰۰۰ (SLEDAI-2K)
حوزه	روماتولوژی	روماتولوژی	روماتولوژی	روماتولوژی
خانواده	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
سال پیدایش	1994	1995	2008	2002
پدیدآور	Garrett et al.	Prevoo et al.	Pincus et al.	Gladman et al.
نوع	Patient-reported outcome (PRO)	Clinician-rated	Patient-reported outcome (PRO)	Clinician-rated
منبع بنیادین	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.	Pincus T, Bergman MJ, Sokka T, Roth SH, Swearingen C, Yazici Y. Activity of rheumatoid arthritis is similar in patients seen in a primary care physician-based practice and in an academic rheumatology-based practice. Arthritis Care Research. 2008;59(9):1229-1236.	Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291.
نام‌های دیگر	BASDAI, BAS-DAI	DAS28, DAS28-CRP, DAS28-ESR	RAPID3, RAPID-3	SLEDAI, SLEDAI-2K, SLE Disease Activity Index
مرتبط	4	3	3	3
خلاصه	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.	RAPID3 is a patient-reported outcome (PRO) measure of rheumatoid arthritis disease activity based on three simple self-report items: patient-counted swollen and tender joints and overall health assessment. Introduced by Pincus et al. in 2008, RAPID3 was designed for primary care and busy practices where joint examination is impractical or time-limited. Remarkably, RAPID3 correlates strongly with clinician-examined composite measures (DAS28, CDAI, SDAI) and predicts long-term radiographic progression equally well, making it a practical alternative for resource-limited settings and self-directed monitoring.	The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease.